The primary purpose of the Animal Resources Core is to facilitate cancer relevant animal projects at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The Johns Hopkins Department of Research Animal Resources oversees all laboratory animal resources and services of The Johns Hopkins University (JHU), including the SKCCC Animal Resources Core. However, due to the unique programs and goals of the SKCCC Animal Resources Core, it is managed as a separate functional unit, under the direction of the Associate Provost for Research Animal Resources and the SKCCC, and is designed specifically to enable investigator- initiated cancer therapeutic investigations in animals. The SKCCC animal care program and facilities are reviewed alongside Research Animal Resources and are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. The SKCCC Animal Resources Core is located in two buildings: 1) the ground level of the SKCCC Cancer Research Building I (CRBI), which contains 8,069 net ft2 of space, and 2) the basement level of the SKCCC Cancer Research Building II (CRBII) which contains 29,831 net ft2 of space. Services provided include animal procurement, daily care and oversight, microbiological and sentinel monitoring, veterinary and pathology services, training and assistance with animal handling and technical procedures, maintenance of genetically altered and immunodeficient rodent breeding colonies, cross-fostering of rodent pups, and management of special facilities for the use of BSL2 and BSL3 hazardous agents. The veterinary, microbiological monitoring and pathology services are performed by the Johns Hopkins Department of Research Animal Resources on a fee-for-service basis. Cynthia Zahnow, Ph.D., Core Director, is responsible for the overall management and direction of the SKCCC Animal Resources Core. Sherrie Hawkes is Supervisor of the Animal Resources Core and is responsible for the day-to-day direction and operation of the Core. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-54
Application #
9278333
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
54
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications